In late September 2026, the US FDA reported that GE HealthCare initiated a voluntary Class II recall of its Centricity PACS imaging software worldwide after discovering that, under certain conditions, migrated historical imaging data could be linked to the wrong patient, potentially leading to misdiagnosis or delayed care across 1,443 systems. On the same week, GE HealthCare also announced a 14% increase in its quarterly dividend to US$0.04 per share and the upcoming addition of experienced finance leader Pascal Desroches to its board in early 2027, underscoring governance and capital-return decisions as it addresses this software safety issue.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.